| Name | Title | Contact Details |
|---|
One of the Worlds Largest Golf Simulator Companies, founded in South Korea in 2000. Winner of five consecutive Golf Digest Awards for Best Golf Simulator (2017-2021). We have over 9,449 sites worldwide, in 41 countries, with 47,500 simulators in operation. Over 99 million rounds are played annually.
bPrescient is a full-service scientific and technology consultancy dedicated to meeting the information management, data science, and analytics needs of the biotech, pharmaceutical, diagnostics, and healthcare industries. With bPrescients industry-leading ecosystem of experts, we offer a unique combination of both depth and breadth of knowledge to provide comprehensive support across: • The entire drug discovery process (from early-stage research to commercialization) • The diagnostics R&D lifecycle • The innovation challenges of the provider / payer domains At bPrescient, we pride ourselves on solving highly complex and difficult challenges. Our clients trust us to provide effective solutions to the problems they face today while anticipating, and helping them avoid, future challenges that catch many organizations unaware. There are three classes of problems we solve for clients: • Strategic & Advisory • Analytical & Scientific • Systems Integration, Design & Build Central to our model is the building of long-term relationships with our clients, which is why we go above and beyond to deliver exceptional results and value to those who need our assistance. Whether you are facing specific challenges today or are thinking about longer-term strategic goals, bPrescient is here to provide the support you need to succeed in the highly competitive biotech, pharmaceutical, diagnostics, and healthcare industries.
COVE Animal Health is a veterinarian-led network of veterinary hospitals providing integrated primary care, emergency, and specialty services across several states in the Northeastern United States, including Connecticut, Maine, Massachusetts, and Pennsylvania. Originally founded in 1937 as Pieper Veterinary in Middletown, CT, COVE has grown into a multi-state network with over 1,000 team members and four hospital systems. COVE offers a comprehensive range of veterinary services, including routine wellness care, 24/7 emergency services, and advanced specialty care in areas such as internal medicine, ophthalmology, and surgery. The company operates a hub-and-spoke model that ensures seamless coordination among its hospitals, enhancing collaboration and resource sharing. COVE is committed to maintaining local ownership and community connections while fostering a culture of mentorship and professional development for veterinary teams.
LTCG is a leading provider of business process outsourcing for the insurance industry. The nations largest insurers rely on our unparalleled expertise to help manage their complex long-term care portfolios and maximize financial performance. We also provide clients with advanced risk management insight built upon our unique and proprietary long-term care underwriting and claims databases. LTCG has more than 1.4 million long-term care policies currently under its management, representing nearly 20% of all active policies. We serve over 50 national carriers, including every one of the top 10 insurers in the long-term care market. Our experienced management team, which has worked together for years, includes some of the most recognized and respected leaders in the long-term care industry. And our information systems have been developed specifically to support the intricacies of this unique market. To learn more, visit www.ltcg.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.